长期肺炎死亡指数:社区获得性肺炎患者的多中心国际衍生与验证研究
本研究利用西班牙多中心前瞻性社区获得性肺炎(CAP)队列(1年随访)衍生长期肺炎死亡指数(L-PMI),并在德国CAPNETZ、美国及西班牙COVID-19肺炎队列中外部验证。L-PMI纳入年龄、吸烟史、养老院居住、Charlson合并症指数评分、CURB-65评分、无创或有创机械通气使用及院内心血管事件。衍生队列AUC为0.82(95%CI 0.78-0.85),验证队列AUC范围为0.75至0.88。L-PMI可将患者分为低、中、高风险组,识别出院后1年内死亡风险较高的肺炎患者。
要点
- L-PMI纳入年龄、吸烟史、养老院居住、Charlson合并症指数评分、CURB-65评分、无创或有创机械通气使用及院内心血管事件7项变量。
- 衍生队列出院后长期死亡率为6.3%,L-PMI预测1年死亡的AUC为0.82(95%CI 0.78-0.85)。
- 外部验证队列AUC:CAPNETZ 0.78(95%CI 0.73-0.83)、美国队列0.75(95%CI 0.73-0.77)、COVID-19队列0.88(95%CI 0.84-0.93)。
- CAPNETZ队列仅随访6个月,其出院后长期死亡率为4.4%;美国队列为17.4%,COVID-19队列为3.6%。
- L-PMI可将患者按死亡风险分为低、中、高风险组。
适用人群与场景
- 社区获得性肺炎(CAP)住院患者,源自西班牙多中心前瞻性队列(1年随访)。
- 外部验证人群包括德国CAPNETZ队列、美国队列及西班牙COVID-19肺炎队列。
诊断标准与关键阈值
- L-PMI评分包含:年龄、吸烟史、养老院居住、Charlson合并症指数评分、CURB-65评分、使用无创或有创机械通气、院内发生心血管事件。
- L-PMI将患者按死亡风险分为低风险、中风险和高风险三组。
研究设计与关键结果
- 研究类型:国际多中心衍生与外部验证研究;衍生队列来自西班牙多中心前瞻性CAP研究(1年随访),验证队列为德国CAPNETZ(仅6个月随访)、美国及西班牙COVID-19肺炎队列。
- 出院后长期死亡率:衍生队列6.3%,CAPNETZ队列4.4%,美国队列17.4%,COVID-19队列3.6%。
- 主要终点(1年死亡)区分度:衍生队列AUC 0.82(95%CI 0.78-0.85);CAPNETZ队列AUC 0.78(95%CI 0.73-0.83);美国队列AUC 0.75(95%CI 0.73-0.77);COVID-19队列AUC 0.88(95%CI 0.84-0.93)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列衍生及外部验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- L-PMI可用于识别CAP患者出院后1年内死亡风险,并按低、中、高风险分组。
- L-PMI的预测变量包括住院期间使用无创或有创机械通气及院内发生心血管事件,提示出院规划可参考这些住院期因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Long-term mortality after hospital discharge in community-acquired pneumonia (CAP) is a neglected issue. A validated, accurate score predicting mortality is needed.
OBJECTIVE: To derive and validate the Long-term Pneumonia Mortality Index (L-PMI).
METHODS: L-PMI derivation used data from a Spanish multicenter prospective study on CAP with a 1-year follow-up. A logistic regression model for predicting 1-year mortality risk was developed. Performance of the model was assessed by estimating the area under the receiver operating characteristic curve (AUC). The model was externally validated using 2 independent multicenter CAP cohorts from Germany and the United States (USA), and one COVID-19 pneumonia cohort from Spain. We then derived a score from the model to ease its application.
MEASUREMENTS AND MAIN RESULTS: The long-term mortality rate after discharge was 6.3%, 4.4%, 17.4%, and 3.6% in the derivation, CAPNETZ (only 6 months of follow-up), USA, and COVID-19 cohorts, respectively. The L-PMI included age, smoking history, nursing home residency, Charlson Comorbidity Index score, CURB-65 score, use of noninvasive or invasive mechanical ventilation, and in-hospital cardiovascular events. The L-PMI showed high discrimination for mortality in the derivation cohort (AUC, 0.82 [95% CI, 0.78-0.85]). In the validation cohorts, the AUC (95% CI) ranged from 0.78 (0.73-0.83) to 0.75 (0.73-0.77) for the CAPNETZ and USA cohorts, respectively, and 0.88 (0.84-0.93) for the COVID-19 cohort. L-PMI allows classification of patients according to their mortality risk into low-, intermediate-, and high-risk groups.
CONCLUSIONS: The L-PMI is a novel clinical prediction score that identifies pneumonia patients at risk of mortality up to 1 year after discharge.
参考来源
- Méndez R, González-Jiménez P, Latorre A, et al. The Long-term Pneumonia Mortality Index: an international multicenter derivation and validation study for patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2026. PMID: 41738235. doi:10.1093/ajrccm/aamag060
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。